Arrowhead to Present at Piper Jaffray Healthcare Conference

PASADENA, Calif. — November 26, 2013 — Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.D., will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4 at 1:30 p.m. EST at the New York Palace Hotel.

A live webcast of the presentation can be accessed by visiting the News & Events section of the company’s website, http://www.arrowheadresearch.com/presentations. A replay will also be archived on the website and available for 90 days.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company’s email list to receive news directly, please send an email to ir@arrowres.com